Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma

Clinical Lymphoma, Myeloma and Leukemia

Volumn 10, Issue 2, 2010, Pages

  Cheung, Matthew C ^a,b   Hicks, Lisa K ^b,c   Leitch, Heather A ^d,e  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d ST PAUL S HOSPITAL   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Bleomycin; Dacarbazine; Doxorubicin; Ritonavir; Saquinavir; Vinblastine; Vinca alkaloid

Indexed keywords

ANTIRETROVIRUS AGENT; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; EMTRICITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; LOPINAVIR PLUS RITONAVIR; OXYCODONE PLUS PARACETAMOL; TENOFOVIR; TRIMETHOPRIM; VINBLASTINE; CHLORMETHINE; CYTOCHROME P450; DIDANOSINE; ETOPOSIDE; GALLIUM; ISOENZYME; NARCOTIC ANALGESIC AGENT; OXYCODONE; PARACETAMOL; PREDNISONE; RITONAVIR; STAVUDINE; VINCA ALKALOID; ZALCITABINE; ANTINEOPLASTIC AGENT; PROTEINASE INHIBITOR;

ABDOMINAL DISTENSION; ABDOMINAL RADIOGRAPHY; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; COLON DILATATION; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ILEOSTOMY; MALE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; PNEUMOCYSTIS PNEUMONIA; VIRUS LOAD; ACETABULUM; ASCENDING COLON; BONE MARROW; CANCER STAGING; CD4 LYMPHOCYTE COUNT; CERVICAL LYMPHADENOPATHY; COLON RESECTION; DISEASE ASSOCIATION; DRUG METABOLISM; DRUG WITHDRAWAL; ENZYME INHIBITION; FATIGUE; FEBRILE NEUTROPENIA; HEPATITIS C; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; ILEUM RESECTION; IMMUNOCOMPETENT CELL; KNEE PAIN; LAPAROTOMY; LIVER HILUS; LYMPH NODE BIOPSY; NODULAR SCLEROSIS HODGKIN LYMPHOMA; PNEUMOCYSTIS JIROVECI; PROPHYLAXIS; SWEAT; TRANSVERSE COLON; B CELL LYMPHOMA; INCIDENCE; NEOPLASM; PATHOLOGY; TOXICITY AND INTOXICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; HIV INFECTIONS; HODGKIN DISEASE; HUMANS; INCIDENCE; LYMPHOMA, AIDS-RELATED; MALE; NEOPLASMS; NEUROTOXICITY SYNDROMES; PROTEASE INHIBITORS; VINBLASTINE;

EID: 77954666053     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2010.n.025     Document Type: Article

References (30)

1. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006;20:1645-54.
2. Biggar RJ, Jaffe ES, Goedert JJ, et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 2006;108:3786-91.
3. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000;92:1823-30.
4. Herida M, Mary-Krause M, Kaphan R, et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003;21:3447-53.
5. Levine AM. AIDS-related lymphoma and Hodgkin's disease. ASH Education Book;2003:304-13.
6. Cheung MC, Imrie KR, Leitch HA, et al. Physician perceptions and preferences in the treatment of acquired immunodeficiency syndrome (AIDS)-related lymphoma. Ann Hematol 2007;86:631-8.
7. Antoniou T, Tseng AL. Interactions between antiretrovirals and antineoplastic drug therapy. Clin Pharmacokinet 2005;44:111-45.
8. Dal Maso L, Clifford G, Polesel J, et al. Effect of individual HAART treatment on Hodgkin and non-Hodgkin lymphoma risk among HIV patients. Ann Oncol 2005;16(suppl 5):v28a.
9. Cheung MC, Pantanowitz L, Dezube BJ. AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy. Oncologist 2005;10:412-26.
10. Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003;101:4653-9.
11. Dunleavy K, Little R, Gea-Banacloche J, et al. Abbreviated treatment with short-course dose-adjusted EPOCH and rituximab (DA-EPOCH-R) is highly effective in AIDS-related lymphoma (ARL). Blood 2004;104:850a (abstract 3111).
12. Ezzat H, Filipenko D, Vickars L, et al. Improved survival in HIV-associated diffuse large B-Cell lymphoma with the addition of rituximab to chemotherapy in patients receiving highly active antiretroviral therapy. HIV Clin Trials 2007;8:132-44.
13. Hoffmann C, Chow KU, Wolf E, et al. Strong impact of highly active antiretrovi-ral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease. Br J Haematol 2004;125:455-62.
14. Xicoy B, Ribera JM, Miralles P, et al. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. Haematologica 2007;92:191-8.
15. Tanaka PY, Pessoa VP, Jr, Pracchia LF, et al. Hodgkin lymphoma among patients infected with HIV in post-HAART era. Clin Lymphoma Myeloma 2007;7:364-8.
16. Spina M, Gabarre J, Rossi G, et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood 2002;100:1984-8.
17. Marti-Carvajal AJ, Cardona AF, Rodriguez ML. Interventions for treating AIDS-associated Hodgkin s lymphoma in treatment-naive adults. Cochrane Database Syst Rev 2007;CD006149.
18. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodg-kin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-84.
19. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003;21:607-14.
20. Gobbi PG, Levis A, Chisesi T, et al. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate-and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 2005;23:9198-207.
21. Johnson PW, Radford JA, Cullen MH, et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol 2005;23:9208-18.
22. Yao D, Ding S, Burchell B, et al. Detoxication of vinca alkaloids by human P450 CYP3A4-mediated metabolism: implications for the development of drug resistance. J Pharmacol Exp Ther 2000;294:387-95.
23. Kajita J, Kuwabara T, Kobayashi H, et al. CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metab Dispos 2000;28:1121-7.
24. Villikka K, Kivisto KT, Maenpaa H, et al. Cytochrome P450-inducing anti-epileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharmacol Ther 1999;66:589-93.
25. Zhou-Pan XR, Seree E, Zhou XJ, et al. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res 1993;53:5121-6.
26. Ezzat H, Cheung MC, Hicks LK, et al. Incidence, Predictors, and Significance of Severe Toxicity in Patients with HIV-Associated Hodgkin Lymphoma. Blood 2008;112:897 (abstract 2587).
27. Kamaluddin M, McNally P, Breatnach F, et al. Potentiation of vincristine toxic-ity by itraconazole in children with lymphoid malignancies. Acta Paediatr 2001;90:1204-7.
28. Bohme A, Ganser A, Hoelzer D. Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Ann Hematol 1995;71:311-2.
29. Cooper CL, van Heeswijk RP, Gallicano K, et al. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis 2003;36:1585-92.
30. Yarchoan R, Tosato G, Little RF. Therapy insight: AIDS-related malignancies -the influence of antiviral therapy on pathogenesis and management. Nat Clin Pract Oncol 2005;2:406-15.